Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
48 hedge funds and large institutions have $151M invested in Agile Therapeutics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 2 reducing their positions, and 8 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 2
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
7% more funds holding
Funds holding: 45 → 48 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less capital invested
Capital invested by funds: $161M → $151M (-$10.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$9.06M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.04M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$6.87M |
| 4 |
PAI
ProQuest Associates IV
Naples,
Florida
|
+$2.54M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.93M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.27M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$980K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$106K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$90.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $1K | -$12.9K | -1 | Closed |
|
52
BlackRock
New York
| $1K | – | – | – |
|
53
Geode Capital Management
Boston,
Massachusetts
| $525 | +$168K | +13 | +45% |
|
|
OM
54
Opaleye Management
Boston,
Massachusetts
| – | -$2.93M | -150 | Closed |
|
|
55
Marshall Wace
London,
United Kingdom
| – | -$1.27M | -65 | Closed |
|
|
HCMT
56
Highland Capital Management (Texas)
Dallas,
Texas
| – | -$980K | -50 | Closed |
|
|
57
Citadel Advisors
Miami,
Florida
| – | -$106K | -5 | Closed |
|
58
BNP Paribas Financial Markets
Paris,
France
| – | -$18.4K | -1 | Closed |
|
59
Bank of America
Charlotte,
North Carolina
| – | -$2K | – | – |
|
AGRX Hedge Fund Activity: Q1 2016 in Review
48 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2016, worth a combined $151M — down 6.5% from $161M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AGRX positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 2 trimmed.
The largest buyer was Caxton Corporation, adding an estimated $9.06M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.93M sold.
- 48 institutional investors held Agile Therapeutics (AGRX) as of Q1 2016, up from 45 in Q4 2015.
- Funds reported $151M of Agile Therapeutics stock for Q1 2016, down 6.5% quarter-over-quarter.
- 11 funds opened new Agile Therapeutics positions in Q1 2016 and 8 closed out, a net change of +3 holders.
- The largest Agile Therapeutics buyer in Q1 2016 was Caxton Corporation, an estimated $9.06M added.
- The largest Agile Therapeutics seller in Q1 2016 was Opaleye Management, an estimated $2.93M sold.
Based on aggregated 13F filings for Q1 2016.